Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Fox Chase Cancer Center, Filadelfia, Pennsylvania, United States
CancerSpectrum Knowledge Environment (Impact Factor: 15.16). 12/2005; 97(22):1652-62. DOI: 10.1093/jnci/dji372
Source: PubMed

ABSTRACT Initial findings from the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial (P-1) demonstrated that tamoxifen reduced the risk of estrogen receptor-positive tumors and osteoporotic fractures in women at increased risk for breast cancer. Side effects of varying clinical significance were observed. The trial was unblinded because of the positive results, and follow-up continued. This report updates our initial findings.
Women (n = 13,388) were randomly assigned to receive placebo or tamoxifen for 5 years. Rates of breast cancer and other events were compared by the use of risk ratios (RRs) and 95% confidence intervals (CIs). Estimates of the net benefit from 5 years of tamoxifen therapy were compared by age, race, and categories of predicted breast cancer risk. Statistical tests were two-sided.
After 7 years of follow-up, the cumulative rate of invasive breast cancer was reduced from 42.5 per 1000 women in the placebo group to 24.8 per 1000 women in the tamoxifen group (RR = 0.57, 95% CI = 0.46 to 0.70) and the cumulative rate of noninvasive breast cancer was reduced from 15.8 per 1000 women in the placebo group to 10.2 per 1000 women in the tamoxifen group (RR = 0.63, 95% CI = 0.45 to 0.89). These reductions were similar to those seen in the initial report. Tamoxifen led to a 32% reduction in osteoporotic fractures (RR = 0.68, 95% CI = 0.51 to 0.92). Relative risks of stroke, deep-vein thrombosis, and cataracts (which increased with tamoxifen) and of ischemic heart disease and death (which were not changed with tamoxifen) were also similar to those initially reported. Risks of pulmonary embolism were approximately 11% lower than in the original report, and risks of endometrial cancer were about 29% higher, but these differences were not statistically significant. The net benefit achieved with tamoxifen varied according to age, race, and level of breast cancer risk.
Despite the potential bias caused by the unblinding of the P-1 trial, the magnitudes of all beneficial and undesirable treatment effects of tamoxifen were similar to those initially reported, with notable reductions in breast cancer and increased risks of thromboembolic events and endometrial cancer. Readily identifiable subsets of individuals comprising 2.5 million women could derive a net benefit from the drug.

Download full-text


Available from: Walter M Cronin, Jan 28, 2015
1 Follower
  • Source
    • "In traditional medicinal systems, herbal medicines are used often to treat the symptoms associated with cancer and the side effects of cancer treatment [68]. Herbal formulations used in TCM include mixtures of herbal compounds constituted as decoctions, tea, injections, or capsules, which are purported to possess anticancer compounds and are used alone or as adjuvants to existing chemotherapy regimens to improve efficacy and/or reduce drug-induced toxicity [69]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is a life-threatening disease among women worldwide with annual rates of reported incidence and death increasing alarmingly. Chemotherapy is a recommended and effective treatment option for breast cancer; however, the narrow therapeutic indices and varied side effects of currently approved drugs present major hurdles in increasing its effectiveness. An increasing number of literature evidence indicate that complementary and alternative medicine (CAM) used in treatment-related symptom control and alleviation of side effects plays an important role in increasing survival rate and quality of life in breast cancer patients. This review focuses on the use of herbal medicines and acupuncture in palliative care and as adjuvants in the treatment of breast cancer. Herbal medicinal treatments, the correlation of clinical use with demonstrated in vitro and in vivo mechanisms of action, and the use of certain acupoints in acupuncture are summarized. The aim of this review is to facilitate an understanding of the current practice and usefulness of herbal medicine and acupuncture as adjuvants in breast cancer therapy.
    Evidence-based Complementary and Alternative Medicine 06/2013; 2013:437948. DOI:10.1155/2013/437948 · 1.88 Impact Factor
  • Source
    • "A meta-analysis conducted by Braithwaite et al. (2003) based on 32 clinical trials and including 52 929 patients has shown that the risk of endometrial cancer is significantly increased in women taking TAM to an estimated relative risk of 2.7. Even if the use of TAM increases the risk of pre-neoplastic and neoplastic endometrial disease, several large-scale randomised clinical trials have shown that the therapeutic benefit of TAM for adjuvant treatment of breast cancer exceeds the risks related to stimulation of the endometrium (Cuzick et al. 2002, Fisher et al. 2005, Bevers et al. 2010, EBCTCG 2011). Despite the widespread use of TAM, there are currently no universally accepted international guidelines for its use, with the exception of the 2006 ACOG committee opinion. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective:To determine the role, timing and indications for endometrial hysteroscopic investigation in relation to the clinical, ultrasound and histological features of the endometrium during tamoxifen use.Methods:We performed an observational longitudinal cohort study (years 2007-2012) that investigated the endometria of 151 tamoxifen users with hysteroscopy and histology. For all patients, gynaecological history, years of adjuvant treatment, ultrasound endometrial thickness measurement and indications for hysteroscopy were recorded.Results:Hysteroscopic findings showed that 100% of patients referred for simple follow-up had no evidence of endometrial disease. We found a strong correlation between previous history of abnormal uterine bleeding (with or without endometrial thickening) and hysteroscopic suspicion of endometrial atypia that was confirmed by histology.Hysteroscopy had 83.3%-sensitivity, 99%-specificity, 83.3%-PPV and 99%-NPV in detecting endometrial atypia. No significant correlation was found between endometrial thickening to >5mm without bleeding and histological atypia. Similarly, the duration of treatment was not related to endometrial thickening and histological atypia.Endometrial stromal hyperplasia was detected by histology in 70.5% of patients with endometrial thickness measurements ranging from 5-10 mm. In contrast, no atypia was detected when endometrial thickness was <5mm.Ultrasound performed using a 5-mm cut-off threshold for endometrial thickness resulted in 100%-sensitivity, 15%-specificity, 4%-PPV and 100%-NPV in detecting endometrial atypia, while a 10-mm cut-off threshold resulted in 84%-sensitivity, 69%-specificity, 10%-PPV and 99%-NPV.Conclusion:Low-risk tamoxifen users do not require different endometrial surveillance than the general population. Hysteroscopy could play a fundamental role in determining the endometrial status of patients before the initiation of tamoxifen treatment and in assessing the endometrial status of patients when bleeding occurs.
    Endocrine Related Cancer 04/2013; 20(4). DOI:10.1530/ERC-13-0020 · 4.91 Impact Factor
  • Source
    • "The critical role of estrogen in human breast cancer is undisputed. The practical consequences of the concept of inhibiting the mitogenic action of estrogen on breast cancer cells have been the successful establishment of the endocrine therapies for treating breast cancer (Trialists&apos; 1992, 1998) as well as providing options for preventing breast cancer (Fisher et al. 2005). While the concept itself is relatively simple, our understanding of the exact molecular mechanisms by which estrogen is involved in these processes continues to evolve and is more complex and multifaceted than originally thought (Zwart et al. 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite over 15 years of research, the exact role, if any, played by ER beta in human breast cancer remains elusive. A large body of data both in vitro and in vivo support its role as an anti-proliferative, pro-apoptotic factor especially when co-expressed with ER alpha. However, there is a smaller body of data associating ER beta with growth and survival in breast cancer. In clinical studies and most often in cell culture studies the pro-growth and pro-survival activity of ER beta occurs in ER alpha negative breast cancer tissue and cells. This bi-faceted role of ER beta is discussed in the following review.
    Endocrine Related Cancer 03/2013; 20(3). DOI:10.1530/ERC-12-0389 · 4.91 Impact Factor
Show more